Latge Adrien, Riehm Sophie, Vix Michel, Bani Jacob, Ignat Mihaela, Pretet Valentin, Helali Mehdi, Treglia Giorgio, Imperiale Alessio
Department of Nuclear Medicine and Molecular Imaging, Institut de Cancérologie de Strasbourg Europe (ICANS), Strasbourg University Hospitals, 67033 Strasbourg, France.
Department of Radiology, Strasbourg University Hospitals, 67098 Strasbourg, France.
Diagnostics (Basel). 2021 Dec 17;11(12):2384. doi: 10.3390/diagnostics11122384.
Patients with primary hyperparathyroidism (pHPT) can develop persistent (P-pHPT) or recurrent (R-pHPT) disease after parathyroidectomy. Before recommending reoperation, recurrence must be accurately identified because of the high risk of complications. Our study evaluates F-fluorocholine (F-FCH) PET/CT and 4D-CT integrated in PET/4D-CT in patients with P-pHPT/R-pHPT. Patients with P-pHPT/R-pHPT investigated by F-FCH PET/4D-CT between May 2018 and March 2021 were retrospectively included. Forty-two patients were included, 37 of whom underwent 4D-CT. The sensitivity and detection rate (DR%) were 95% and 88% for F-FCH PET/CT and 70% and 63% for 4D-CT, respectively. PET/CT and 4D-CT were concordant in 18/24 glands and concordant and positive in 15/24 (63%) glands. Discordant results were obtained for 6/24 glands. The surgical success rate was 65%. PET/CT showed significantly higher sensitivity than 4D-CT. Dynamic CT allowed the identification of no additional glands missed by PET/CT, and the combination of the 2 techniques did not improve the sensitivity or DR%. F-FCH PET/CT appears to be a valuable technique to accurately detect hyperfunctioning parathyroid tissue in patients with P-pHPT/R-pHPT and is better than 4D-CT. Except for cases with doubtful locations of PET targets that may require 4D-CT for surgical guidance, standard nonenhanced F-FCH PET/CT can be effectively recommended in patients with P-pHPT/R-pHPT before reoperation.
原发性甲状旁腺功能亢进症(pHPT)患者在甲状旁腺切除术后可能会出现持续性(P-pHPT)或复发性(R-pHPT)疾病。在建议再次手术之前,由于并发症风险高,必须准确识别复发情况。我们的研究评估了F-氟胆碱(F-FCH)PET/CT以及PET/4D-CT中整合的4D-CT在P-pHPT/R-pHPT患者中的应用。回顾性纳入了2018年5月至2021年3月期间接受F-FCH PET/4D-CT检查的P-pHPT/R-pHPT患者。纳入42例患者,其中37例接受了4D-CT检查。F-FCH PET/CT的敏感性和检出率(DR%)分别为95%和88%,4D-CT的敏感性和检出率分别为70%和63%。PET/CT和4D-CT在24个腺体中的18个上结果一致,在24个腺体中的15个(63%)上结果一致且为阳性。24个腺体中有6个结果不一致。手术成功率为65%。PET/CT的敏感性显著高于4D-CT。动态CT未能识别出PET/CT遗漏的额外腺体,两种技术联合使用并未提高敏感性或检出率。F-FCH PET/CT似乎是准确检测P-pHPT/R-pHPT患者甲状旁腺功能亢进组织的一种有价值的技术,且优于4D-CT。除了PET靶点位置可疑可能需要4D-CT进行手术指导的情况外,对于P-pHPT/R-pHPT患者在再次手术前可有效推荐标准的非增强F-FCH PET/CT。